Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation

European Journal of Clinical Pharmacology

Volumn 61, Issue 7, 2005, Pages 507-516

  Staatz, Christine E ^a   Duffull, Stephen B ^a   Kiberd, Bryce ^b   Fraser, Albert D ^b   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SERUM ALBUMIN; TACROLIMUS;

ACCURACY; ADULT; AGED; ARTICLE; BODY WEIGHT; CADAVER DONOR; COVARIANCE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEMOGRAPHY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENTEROHEPATIC CIRCULATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; POPULATION RESEARCH; PRIORITY JOURNAL; VALIDATION PROCESS;

ADULT; AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NOVA SCOTIA; POPULATION SURVEILLANCE;

EID: 24044481344     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0927-4     Document Type: Article

References (25)

1. Bullingham RES, Nicholls A, Hale M (1996) Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 28:925-929
2. Johnson AG, Rigby RJ, Taylor PJ et al (1999) The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther 66:492-500
3. Mourad M, Malaise J, Eddour D et al (2001) Pharmacokinetic basis for the efficient and safe use of low dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 47:1241-1248
4. Cattaneo D, Gaspari F, Ferrari S et al (2001) Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clin Transplant 15:402-409
5. Pillans PI, Rigby RJ, Kubler P et al (2001) The relationship between mycophenolic acid area under concentration-time curve and trough cyclosporine concentrations with biopsy proven rejection in the first month following renal transplantation. Clin Biochem 34:77-81
6. van Gelder T, Hilbrands LB, Vanrenterghem Y et al (1999) A randomised double-blinded, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68:261-266
7. Hale MD, Nicholls AJ, Bullingham RE et al (1998) The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64:672-683
8. Weber LT, Shipkova M, Armstrong VW et al (2002) The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 13:759-769
9. Shaw LM, Holt DW, Oellerich M et al (2001) Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23:305-315
10. Cox VC, Ensom MH (2003) Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 18:266-272
11. Willis C, Taylor P, Salm P et al (2000) Evaluation of limited sampling strategies for estimation of 12 hour mycophenolic acid area under the plasma concentration time curve in adult renal transplant patients. Ther Drug Monit 22:549-554
12. Thomson AH, Whiting B (1992) Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet 22:447-467
13. Shum B, Duffull SB, Taylor PJ, Tett SE (2003) Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. Br J Clin Pharmacol 56:188-197
14. Le Guellec C, Bourgoin H, Büchler M et al (2004) Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentration in stable renal transplant patients. Clin Pharmacokinet 43:253-266
15. Nowak I, Shaw LM (1995) Mycophenolic acid binding in human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 41:1011-1017
16. Weber LT, Shipkova M, Lamersdorf T et al (1998) Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in paediatric and adult renal transplant recipients. German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. J Am Soc Nephrol 9:1511-1520
17. Weber LT, Lamersdorf T, Shipkova M et al (1999) Area under the plasma concentration-curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in paediatric patients. German study group on mycophenolate mofetil therapy in pediatric renal transplant recipients. Ther Drug Monit 21:498-506
18. Atcheson BA, Taylor PJ, Kirkpatrick CMJ et al (2004) Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminaemia. Ther Drug Monit 26:284-286
19. Svensson J-O, Braltstrum C, Sawe J (1999) A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monit 21:322-324
20. Efron B (1979) Bootstrap methods: another look at the jacknife. Ann Stat 7:1-26
21. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
22. Van Gelder T, Klupp J, Barten MJ et al (2001) Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23:119-128
23. Filler G, Zimmering M, Mai I (2000) Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 14:100-104
24. Meier-Kriesche HU, Shaw LM, Korecka M, Kaplan B (2000) Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit 22:27-30
25. Shaw LM, Korecka M, Aradhye S et al (2000) Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable. J Clin Pharmacol 40:624-633